Featured Trial
Esophagus and Stomach Cancer Treatment

Featured Trial
Liver Cancer Treatment

Featured Trial
Survey on COVID-19 Related Distress

Featured Trial
Self-Reported Data by Young Adults

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Resources for Active Trials

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
PRO Research Overview

Specialty Presentation:
Implementation Science

Latest News

August 10, 2022

Categories

President Biden announces his intent to appoint Dr. Monica Bertagnolli as the next NCI director

August 9, 2022

Categories

Announcements

Early-career investigators: Submit an abstract for the 2022 Young Investigator Symposium by Wednesday, 9/7

July 21, 2022

Categories

Group co-chairs Peter O’Dwyer and Mitch Schnall commend the selection of Monica Bertagnolli as the next NCI director

July 15, 2022

Categories

News Stories

Ongoing Smoke Free Support Study 2.0 featured in BioMed Central’s Public Health Journal

July 2, 2022

Categories

News Stories

What is ECOG-ACRIN EA2142? And why should you care?

Tweets

ECOG-ACRIN Cancer Research Group Follow

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc ·

If successful, the FEATURE trial could allow patients w/ bone-dominant metastatic #breastcancer–who are often excluded from clinical trials–to participate in multicenter studies w/ the potential to achieve improved outcomes for these patients. Learn more: https://bit.ly/feature-study

Reply on Twitter 1557441987087052800 Retweet on Twitter 1557441987087052800 Like on Twitter 1557441987087052800 Twitter 1557441987087052800

ECOG-ACRIN Cancer Research Group @eaonc ·

https://cancerletter.com/white-house/20220810_1/

Reply on Twitter 1557428739092480002 Retweet on Twitter 1557428739092480002 Like on Twitter 1557428739092480002 Twitter 1557428739092480002

ECOG-ACRIN Cancer Research Group @eaonc ·

Congratulations, Dr. Bertagnolli! President Biden Intends to Appoint Dr. Monica Bertagnolli as Director of the National Cancer Institute https://www.whitehouse.gov/briefing-room/statements-releases/2022/08/10/president-biden-intends-to-appoint-dr-monica-bertagnolli-as-director-of-the-national-cancer-institute/?utm_source=twitter via @whitehouse

Reply on Twitter 1557428573140656131 Retweet on Twitter 1557428573140656131 Like on Twitter 1557428573140656131 1 Twitter 1557428573140656131

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1300

Participating Institutions

International Sites

15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).